Posting of Annual Report and Notice of AGM

SkinBioTherapeutics PLC

04 December 2024

 

SkinBioTherapeutics plc

Posting of Annual Report and AGM Notice

4 December 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), a life science company focused on skin health, confirms that the Notice of Annual General Meeting ("AGM"), form of proxy and Annual Report and Accounts for the year ended 30 June 2024 have been posted to shareholders.

An electronic copy of the Annual Report and Accounts and the Notice of AGM will also be available on the Company's website - https://www.skinbiotherapeutics.com/investor-relations.

The AGM will be held at 10:00am on Friday 27 December 2024 at The Clarion Hotel, Witney Way, Boldon, NE35 9PE.

-Ends-

For more information please contact: SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO Tel: [phone] Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales) Tel: [phone] Vigo Consulting (financial press) Rozi Morris Tel: [phone] [e-mail] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis. The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.   The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:www.skinbiotherapeutics.com.

 

END